|
已读[365]
发布： 2013/07/04 17:52:33
OPTIMOX1临床研究采用随机对照方法,在累积神经毒性出现前停止给予含奥沙利铂的FOLFOX7方案,然后用LV5鄄FU2维持治疗共12周期,在疾病进展前、神经感觉异常基本恢复后再次...
|
|
|
|
|
已读[81]
发布： 2013/07/03 20:58:50
ScoopSanDiego.com Do not take REYATAZ (atazanavir sulfate) with the following medicines due to potential for serious side effects:Camptosar® (irinotecan), Crixivan® (indinavir), Mevacor®( lovastatin ), Zocor® (simvastatin), Uroxatral® (alfuzosin), or Revatio® (sildenafil).
|
|
|
|
|
已读[46]
发布： 2013/06/22 13:35:45
美国临床肿瘤学会年会上一位研究者报道说:在延缓甲基鸟嘌呤甲基转移酶未分化恶性胶质瘤患者病情进展方面,贝伐单抗联合伊立替康治疗明显优于替莫唑胺。 德国波恩大学神经科Ulrich Herrlinger博士报道说:在第Ⅱ阶段的GLARIUS试验中,与41.3%随机接受替莫唑胺治疗(P<0.0001)的患者相比,...
|
|
|
|
|
已读[189]
发布： 2013/06/22 13:35:36
另外公司也致力于逐步把企业主力产品推向欧美主流市场,公司伊立替康和奥沙利铂注射液分别是中国首次获准在美国和欧盟的注射剂,目前有多个车间及品种在申请认证,未来国际市场销售也有望成为公司利润增长点。 华东医药000963,公司是国内化学仿制药领域的龙头企业,...
|
|
|
|
|
已读[38]
发布： 2013/06/22 13:35:32
其中伊立替康2011年通过FDA认证,2012年奥沙利铂和来曲唑通过欧盟认证,2013年来曲唑通过FDA认证,近期老产品环磷酰胺完成欧盟现场检查,下半年将迎接FDA现场检查,有望明年同时在美国和欧盟上市。 人才战略:公司专业研发人员1200多人,加上现场技术人员共有1300余人,...
|
|
|
|
|
已读[32]
发布： 2013/06/22 13:35:28
4-traders (press release) Both ADC product candidates involve SN-38, the active metabolite of irinotecan (used to treat metastatic colorectal and other solid cancers), conjugated by the Company's proprietary technology to labetuzumab (anti-CEACAM5 humanized monoclonal ... and more »
|
|
|
|
|
已读[31]
发布： 2013/06/22 13:35:07
Irish Medical Times These have included biologic therapies such as bevacizumab and both oxaliplatin and irinotecan are effective. In large studies of metastatic colon cancer, up to 10 per cent of patients had peritoneal carcinomatosis. Overall survival of patients with ...
|
|
|
|
|
已读[30]
发布： 2013/06/22 13:35:03
The Oncology Report CHICAGO – The combination of bevacizumab and irinotecan far outshone tenozolomide in delaying disease progression among patients with MGMT-unmethylated glioblastoma, an investigator reported at the annual meeting of the American Society of ...
|
|
|
|
|
已读[54]
发布： 2013/06/18 22:33:15
(同样在本届ASCO年会上报告的GLARIUS试验结果显示,新诊MGMT未甲基化胶质母细胞瘤患者接受贝伐珠单抗联合伊立替康化放疗其无进展生存期优于于接受替莫唑胺化放疗的患者,初步分析预示着前者同样显示出总生存方面的益处。) 值得指出的是,在RTOG 0825试验中,贝伐珠单抗组患者与对照组相比,...
|
|
|
|
|
已读[35]
发布： 2013/06/18 22:32:48
Medscape ... of the KRAS gene, cetuximab (Erbitux, ImClone Systems) might be more effective than bevacizumab (Avastin, Genentech) when added to FOLFIRI chemotherapy, which is comprised of folinic acid, fluorouracil, and irinotecan , a trial from Germany shows.
|
|
|
« 上一页 |
查看结果51-60共248
|
下一页 »
|
|
